JP2010534478A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010534478A5 JP2010534478A5 JP2010518389A JP2010518389A JP2010534478A5 JP 2010534478 A5 JP2010534478 A5 JP 2010534478A5 JP 2010518389 A JP2010518389 A JP 2010518389A JP 2010518389 A JP2010518389 A JP 2010518389A JP 2010534478 A5 JP2010534478 A5 JP 2010534478A5
- Authority
- JP
- Japan
- Prior art keywords
- binding protein
- seq
- antigen binding
- receptor
- item
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 102000025171 antigen binding proteins Human genes 0.000 claims description 54
- 108091000831 antigen binding proteins Proteins 0.000 claims description 54
- 102000004557 Interleukin-18 Receptors Human genes 0.000 claims description 23
- 108010017537 Interleukin-18 Receptors Proteins 0.000 claims description 23
- 238000000034 method Methods 0.000 claims description 22
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 18
- 239000012634 fragment Substances 0.000 claims description 14
- 102000039446 nucleic acids Human genes 0.000 claims description 12
- 108020004707 nucleic acids Proteins 0.000 claims description 12
- 150000007523 nucleic acids Chemical class 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 102000003810 Interleukin-18 Human genes 0.000 claims description 9
- 108090000171 Interleukin-18 Proteins 0.000 claims description 9
- 102000005962 receptors Human genes 0.000 claims description 7
- 108020003175 receptors Proteins 0.000 claims description 7
- 230000002401 inhibitory effect Effects 0.000 claims description 5
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims description 4
- 208000011231 Crohn disease Diseases 0.000 claims description 4
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 4
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 4
- 201000004681 Psoriasis Diseases 0.000 claims description 4
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 4
- 201000008937 atopic dermatitis Diseases 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 206010025135 lupus erythematosus Diseases 0.000 claims description 4
- 201000006417 multiple sclerosis Diseases 0.000 claims description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 4
- 101000960954 Homo sapiens Interleukin-18 Proteins 0.000 claims description 2
- 125000000539 amino acid group Chemical group 0.000 claims description 2
- 102000043959 human IL18 Human genes 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 4
- 206010003549 asthenia Diseases 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 210000003205 muscle Anatomy 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 description 4
- 208000024172 Cardiovascular disease Diseases 0.000 description 4
- 208000016222 Pancreatic disease Diseases 0.000 description 4
- 208000019423 liver disease Diseases 0.000 description 4
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 208000000668 Chronic Pancreatitis Diseases 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 2
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 2
- 206010033645 Pancreatitis Diseases 0.000 description 2
- 206010033647 Pancreatitis acute Diseases 0.000 description 2
- 206010033649 Pancreatitis chronic Diseases 0.000 description 2
- 206010063837 Reperfusion injury Diseases 0.000 description 2
- 208000035868 Vascular inflammations Diseases 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 201000003229 acute pancreatitis Diseases 0.000 description 2
- 230000036523 atherogenesis Effects 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 206010028417 myasthenia gravis Diseases 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 201000000306 sarcoidosis Diseases 0.000 description 2
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US95169207P | 2007-07-24 | 2007-07-24 | |
| US95169107P | 2007-07-24 | 2007-07-24 | |
| US7314208P | 2008-06-17 | 2008-06-17 | |
| PCT/US2008/071047 WO2009015284A2 (en) | 2007-07-24 | 2008-07-24 | Il-18 receptor antigen binding proteins |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014182029A Division JP2015015957A (ja) | 2007-07-24 | 2014-09-08 | Ｉｌ−１８受容体抗原結合タンパク質 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010534478A JP2010534478A (ja) | 2010-11-11 |
| JP2010534478A5 true JP2010534478A5 (enExample) | 2011-09-01 |
Family
ID=40282148
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010518389A Ceased JP2010534478A (ja) | 2007-07-24 | 2008-07-24 | Ｉｌ−１８受容体抗原結合タンパク質 |
| JP2014182029A Pending JP2015015957A (ja) | 2007-07-24 | 2014-09-08 | Ｉｌ−１８受容体抗原結合タンパク質 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014182029A Pending JP2015015957A (ja) | 2007-07-24 | 2014-09-08 | Ｉｌ−１８受容体抗原結合タンパク質 |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US8257707B2 (enExample) |
| EP (1) | EP2178917A4 (enExample) |
| JP (2) | JP2010534478A (enExample) |
| KR (1) | KR20100049535A (enExample) |
| CN (1) | CN101835489B (enExample) |
| AR (1) | AR067666A1 (enExample) |
| AU (1) | AU2008279127B2 (enExample) |
| BR (1) | BRPI0813016A2 (enExample) |
| CA (1) | CA2693503A1 (enExample) |
| CL (1) | CL2008002153A1 (enExample) |
| EA (1) | EA016783B1 (enExample) |
| IL (1) | IL202833A0 (enExample) |
| PE (1) | PE20090518A1 (enExample) |
| SG (1) | SG183070A1 (enExample) |
| TW (1) | TWI436778B (enExample) |
| WO (1) | WO2009015284A2 (enExample) |
| ZA (1) | ZA201001140B (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7968684B2 (en) | 2003-11-12 | 2011-06-28 | Abbott Laboratories | IL-18 binding proteins |
| AR082518A1 (es) | 2010-08-25 | 2012-12-12 | Hoffmann La Roche | Anticuerpos contra il-18r1 y usos de los mismos |
| SG10202006507XA (en) | 2012-05-30 | 2020-08-28 | Chugai Pharmaceutical Co Ltd | Target-tissue-specific antigen-binding molecule |
| US8821242B2 (en) | 2012-07-25 | 2014-09-02 | Lumos Labs, Inc. | Systems and methods for enhancing cognition |
| UY35148A (es) | 2012-11-21 | 2014-05-30 | Amgen Inc | Immunoglobulinas heterodiméricas |
| WO2014144817A2 (en) | 2013-03-15 | 2014-09-18 | Amgen Inc. | Inhibitory polypeptides specific to wnt inhibitors |
| KR102085179B1 (ko) * | 2013-05-07 | 2020-04-16 | 삼성전자주식회사 | 디바이스의 위치에 기초한 콘텐트 제공 시스템 및 방법 |
| CA2923145C (en) | 2013-09-05 | 2025-09-16 | Amgen Inc. | MOLECULES CONTAINING FCS AND EXHIBITING PREDICTABLE, UNIFORM AND REPRODUCIBLE GLYCOFORM PROFILES |
| AU2014358191B2 (en) | 2013-12-04 | 2020-12-24 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecules, the antigen-binding activity of which varies according to the concentration of compounds, and libraries of said molecules |
| MX377275B (es) | 2014-05-16 | 2025-03-07 | Amgen Inc | Ensayo para detectar poblaciones celulares linfocitos t colaboradores 1 (th1) y linfocitos t colaboradores (th2). |
| US10792100B2 (en) | 2014-08-20 | 2020-10-06 | Covidien Lp | Systems and methods for spherical ablations |
| KR20160047889A (ko) * | 2014-10-23 | 2016-05-03 | 삼성전자주식회사 | 전자 장치 및 피공유자 추천 서비스 운용 방법 |
| AU2018235928B2 (en) | 2017-03-14 | 2023-09-21 | Amgen Inc. | Control of total afucosylated glycoforms of antibodies produced in cell culture |
| CN119639849A (zh) | 2018-03-26 | 2025-03-18 | 美国安进公司 | 细胞培养物中产生的抗体的总去岩藻糖基化糖型 |
| WO2019242655A1 (en) * | 2018-06-19 | 2019-12-26 | Shanghaitech University | Human antibodies to human interleukin 18 receptor alpha and beta |
| PT3618928T (pt) | 2018-07-13 | 2023-03-29 | Alector Llc | Anticorpos anti-sortilina e métodos de utilização dos mesmos |
| IL317002A (en) | 2018-08-10 | 2025-01-01 | Chugai Pharmaceutical Co Ltd | Anti-CD137 antigen binding molecule and use thereof |
| AU2020355251A1 (en) | 2019-09-26 | 2022-04-21 | Amgen Inc. | Methods of producing antibody compositions |
| WO2021247892A1 (en) | 2020-06-04 | 2021-12-09 | Amgen Inc. | Assessment of cleaning procedures of a biotherapeutic manufacturing process |
| AU2021360897A1 (en) | 2020-10-15 | 2023-05-25 | Amgen Inc. | Relative unpaired glycans in antibody production methods |
| CN114736291B (zh) * | 2021-01-07 | 2023-08-11 | 中国科学院微生物研究所 | 特异性结合发热伴血小板减少综合征病毒的囊膜蛋白Gn的人源单克隆抗体及其用途 |
| AR126089A1 (es) | 2021-06-07 | 2023-09-13 | Amgen Inc | Uso de fucosidasa para controlar el nivel de afucosilación de proteínas glucosiladas |
| WO2023059607A1 (en) | 2021-10-05 | 2023-04-13 | Amgen Inc. | Fc-gamma receptor ii binding and glycan content |
| WO2023134767A1 (zh) * | 2022-01-14 | 2023-07-20 | 和径医药科技（上海）有限公司 | 一种靶向IL-18Rβ的抗体及其应用 |
| WO2023215725A1 (en) | 2022-05-02 | 2023-11-09 | Fred Hutchinson Cancer Center | Compositions and methods for cellular immunotherapy |
| WO2024040195A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| AU2024256160A1 (en) | 2023-04-20 | 2025-10-02 | Amgen Inc. | Methods of determining relative unpaired glycan content |
| AU2024325342A1 (en) | 2023-08-14 | 2026-02-26 | Amgen Inc. | Methods for reducing yellow color |
| WO2025101820A1 (en) | 2023-11-08 | 2025-05-15 | Fred Hutchinson Cancer Center | Compositions and methods for cellular immunotherapy |
| WO2026090253A1 (en) | 2024-10-23 | 2026-04-30 | Amgen Inc. | Methods of determining glycan pairing content |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5776731A (en) | 1996-02-21 | 1998-07-07 | Immunex Corporation | DNA encoding type-I interleukin-I receptor-like protein designated 2F1 |
| US7141393B2 (en) | 1996-12-26 | 2006-11-28 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Interleukin-18-receptor proteins |
| AU750767B2 (en) | 1998-01-23 | 2002-07-25 | Immunex Corporation | ACPL DNA and polypeptides |
| ATE272114T1 (de) | 1998-01-23 | 2004-08-15 | Immunex Corp | Rezeptoren für il-18 |
| CA2340579A1 (en) * | 1998-09-01 | 2000-03-09 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Interleukin 18-binding protein |
| IL131047A0 (en) | 1999-07-22 | 2001-01-28 | Yeda Res & Dev | Use of il-18 inhibitors |
| AU7676300A (en) | 1999-10-12 | 2001-04-23 | Cambridge Antibody Technology Limited | Human anti-adipocyte monoclonal antibodies and their use |
| PL356836A1 (en) | 2000-02-10 | 2004-07-12 | Abbott Laboratories | Antibodies that bind human interleukin-18 and methods of making and using |
| AU2001268427B2 (en) * | 2000-06-16 | 2007-03-29 | Glaxosmithkline Intellectual Property Limited | Antibodies that immunospecifically bind to blys |
| CA2422881A1 (en) | 2000-10-13 | 2002-04-18 | Uab Research Foundation | Human anti-epidermal growth factor receptor single-chain antibodies |
| AU2002224417A1 (en) | 2000-10-18 | 2002-04-29 | Immunex Corporation | Methods for treating il-18 mediated disorders |
| CN100556450C (zh) | 2001-05-16 | 2009-11-04 | 耶达研究发展有限公司 | Il-18抑制剂在治疗或预防脓毒症中的应用 |
| US20040023336A1 (en) * | 2001-10-26 | 2004-02-05 | Heavner George A. | Mut-IL-18 or Mut-IL-18R proteins, antibodies, compositions, methods and uses |
| EP1461082A4 (en) * | 2001-12-03 | 2006-06-28 | Abgenix Inc | ANTIBODIES AGAINST THE TUMOR ANTIGEN OF CARBON IX ANHYDRASE (CA IX) |
| CN100558895C (zh) * | 2003-07-18 | 2009-11-11 | 持田制药株式会社 | 抗血小板膜糖蛋白vi单克隆抗体 |
| US7968684B2 (en) | 2003-11-12 | 2011-06-28 | Abbott Laboratories | IL-18 binding proteins |
| EP1808446B1 (en) * | 2004-07-16 | 2012-01-18 | Atsuo Sekiyama | Il-18 receptor antagonist and pharmaceutical composition containing the antagonist |
-
2008
- 2008-07-23 CL CL2008002153A patent/CL2008002153A1/es unknown
- 2008-07-24 CN CN2008800254509A patent/CN101835489B/zh not_active Expired - Fee Related
- 2008-07-24 KR KR1020107000286A patent/KR20100049535A/ko not_active Ceased
- 2008-07-24 CA CA2693503A patent/CA2693503A1/en not_active Abandoned
- 2008-07-24 WO PCT/US2008/071047 patent/WO2009015284A2/en not_active Ceased
- 2008-07-24 JP JP2010518389A patent/JP2010534478A/ja not_active Ceased
- 2008-07-24 EA EA201000238A patent/EA016783B1/ru not_active IP Right Cessation
- 2008-07-24 US US12/670,112 patent/US8257707B2/en not_active Expired - Fee Related
- 2008-07-24 TW TW097128186A patent/TWI436778B/zh not_active IP Right Cessation
- 2008-07-24 AU AU2008279127A patent/AU2008279127B2/en not_active Ceased
- 2008-07-24 EP EP08826644A patent/EP2178917A4/en not_active Withdrawn
- 2008-07-24 PE PE2008001261A patent/PE20090518A1/es not_active Application Discontinuation
- 2008-07-24 BR BRPI0813016A patent/BRPI0813016A2/pt not_active IP Right Cessation
- 2008-07-24 AR ARP080103206A patent/AR067666A1/es not_active Application Discontinuation
- 2008-07-24 SG SG2012054557A patent/SG183070A1/en unknown
-
2009
- 2009-12-20 IL IL202833A patent/IL202833A0/en unknown
-
2010
- 2010-02-17 ZA ZA2010/01140A patent/ZA201001140B/en unknown
-
2012
- 2012-08-20 US US13/589,984 patent/US8540993B2/en not_active Expired - Fee Related
-
2013
- 2013-09-03 US US14/017,014 patent/US20140093915A1/en not_active Abandoned
-
2014
- 2014-09-08 JP JP2014182029A patent/JP2015015957A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023539245A5 (enExample) | ||
| JP2018183173A5 (enExample) | ||
| JP2018521638A5 (enExample) | ||
| JP2019201643A5 (enExample) | ||
| US10544216B2 (en) | P2X7 receptor antagonists and agonists | |
| JP2017501711A5 (enExample) | ||
| JP2018108081A5 (enExample) | ||
| HRP20190605T1 (hr) | Protutijela anti-fxi i postupci njihove uporabe | |
| JP2009523154A5 (enExample) | ||
| JP2016511277A5 (enExample) | ||
| JP2010516229A5 (enExample) | ||
| JP2015504306A5 (enExample) | ||
| JP2018526981A5 (enExample) | ||
| JP2010517513A5 (enExample) | ||
| RU2013110874A (ru) | Антитела против il-18r1 и их применения | |
| JP2014534242A5 (enExample) | ||
| JP2014500009A5 (enExample) | ||
| JP2010524435A5 (enExample) | ||
| JP2012525829A5 (enExample) | ||
| CN101432015A (zh) | 功能性抗体 | |
| MX2007004113A (es) | Antagonistas y metodos para usar los mismos. | |
| JP2011517447A5 (enExample) | ||
| JP2023549537A5 (enExample) | ||
| JP2011518125A5 (enExample) | ||
| JP2024516595A5 (enExample) |